The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05494788
Recruitment Status : Active, not recruiting
First Posted : August 10, 2022
Last Update Posted : May 23, 2024
Information provided by (Responsible Party):
Cardiol Therapeutics Inc.

Brief Summary:
Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol [CBD] solution) is known to have anti-inflammatory properties, including modulation of inflammasome signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the resolution of pericarditis symptoms, assess improvement in objective measures of disease, and during the extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRxTM.

Condition or disease Intervention/treatment Phase
Recurrent Pericarditis Drug: CardiolRx Phase 2

Detailed Description:

Multi-center, open label Pilot Study. Patients who present with recurrent pericarditis will be screened and informed consent obtained.

Baseline assessments include the following: Clinical assessment, including vital signs, highest NRS pain score within the past 7 days of Day 1, 12-lead ECG; C-SSRS as well as hematology and blood chemistry and a pregnancy test for women with child-bearing potential.

Concomitant medications are recorded and any (S)AEs after informed consent has been obtained.

Study treatment will be initiated in the evening of Day 1, after all baseline assessments are completed.

Oral administration is as follows:

  • Initial starting dose (Day 1 p.m. dose to Day 3 a.m. dose):

    5 mg/kg of body weight CardiolRxTM

  • Day 3 p.m. dose to Day 10 a.m. dose: 7.5 mg/kg of body weight CardiolRxTM b.i.d.
  • Day 10 p.m. dose to end of treatment period: 10.0 mg/kg of body weight CardiolRxTM b.i.d.

If the next higher dose after each study drug increase is not tolerated, the dose will be reduced to the previous tolerated dose.

Unless contraindicated in the opinion of the investigator, after 8 weeks of treatment, patients will enter an 18-week extension period (EP), in which they continue study treatment while their concomitant medications will be weaned.

Follow-up Procedures Every visit (before the next dose increase) the patient will be re-evaluated. This includes ECG monitoring at approximately 5 hours post-morning dose (Tmax) to surveil for deleterious effects on ECG intervals (particularly the QTc interval) and rhythm.

Drug titration will be dependent on investigator or designate interrogation of the ECGs and the absence of new, clinically significant abnormalities on those ECGs.

Vital signs, concurrent medication and (S)AEs will be recorded at all visits. Blood chemistry including liver function tests, hematology as well as INR assessments will be carried out at selected visits.

Final efficacy assessments will take place after 26 weeks of study treatment and include a clinical assessment, vital signs, pain score NRS, a 12-lead ECG, the C-SSRS, as well as laboratory assessments.

For patients who do not enter the EP, Final assessments will be done after 8 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open label
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Impact of CardiolRxTM on Recurrent Pericarditis An Open Label Pilot Study (MAvERIC-Pilot Study)
Actual Study Start Date : November 30, 2022
Estimated Primary Completion Date : June 15, 2024
Estimated Study Completion Date : September 15, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: CardiolRx
pharmaceutically produced Cannabidiol
Drug: CardiolRx
Pharmaceutically produced Cannabidiol

Primary Outcome Measures :
  1. 11-point NRS pain score [ Time Frame: 8 weeks ]
    change in patient-reported pericarditis pain using an 11-point NRS from baseline to 8 weeks

Secondary Outcome Measures :
  1. 11-point NRS pain score [ Time Frame: 26 weeks ]
    Pain score using 11-point NRS after 26 weeks of treatment

  2. Percentage of patients with normalized CRP levels [ Time Frame: 8 weeks ]
    Percentage of patients with normalized CRP levels at 8 weeks (for patients with CRP ≥1.0 mg/dL at baseline)

  3. Percentage of patients with pericarditis recurrence during the extension period (EP) [ Time Frame: 26 weeks ]
    Percentage of patients with pericarditis recurrence during the extension period (EP)

  4. Percentage of patients with normalized CRP levels [ Time Frame: 26 weeks ]
    Percentage of patients with normalized CRP levels at 26 weeks (for patients with CRP ≥ 1.0 mg/dL at baseline)

  5. Time to normalized CRP levels [ Time Frame: Over 26 weeks ]
    Time to CRP normalization for patients with CRP ≥1.0 mg/dL at baseline

  6. CRP change from baseline [ Time Frame: 26 weeks ]
    CRP change from baseline (%)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female 18 years of age or older
  2. Diagnosis of at least two episodes of recurrent pericarditis*,
  3. At least 1 day with pericarditis pain ≥4 on the 11-point Numerical Rating Scale (NRS) within prior 7 days
  4. One of;

    1. C-Reactive Protein** (CRP) level ≥1.0 mg/dL within prior 7 days OR
    2. Evidence of pericardial inflammation assessed by delayed pericardial hyperenhancement on cardiac magnetic resonance imaging (CMR)
  5. Currently receiving non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine and/or corticosteroids (in any combination) for treatment of pericarditis in stable doses
  6. Male patients with partners of childbearing potential who have had a vasectomy or are willing to use double barrier contraception methods during the conduct of the study and for 2 months after the last dose of study drug.
  7. Women of childbearing potential willing to use an acceptable method of contraception starting with study drug administration and for a minimum of 2 months after study completion. Otherwise, women must be postmenopausal (at least 1 y absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone [FSH] ≥40 mIU/mL [or ≥ 40 IU/L] if less than 2 y postmenopausal) or be surgically sterile.

    • Diagnosis of pericarditis according to the 2015 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Management of Pericardial Diseases (Adler et al. 2015):

At least two of:

  1. Pericarditic chest pain
  2. Pericardial rub
  3. New widespread ST-segment elevation or PR-segment depression according to electrocardiogram (ECG) findings
  4. Pericardial effusion (new or worsening)

    • Conversion: 1 mg/dL CRP = 10 mg/L hs-CRP

Exclusion Criteria:

  1. Diagnosis of pericarditis that is secondary to specific prohibited etiologies, including tuberculosis (TB); neoplastic, purulent, or radiation etiologies; post-thoracic blunt trauma (e.g., motor vehicle accident); myocarditis
  2. Estimated glomerular filtration rate (eGFR) <30 mL/min at screening
  3. Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN) or ALT or AST >3x ULN plus bilirubin >2x ULN
  4. Sepsis, defined as documented bacteremia at the time of screening or other documented active infection
  5. Prior history of sustained ventricular arrhythmia
  6. History of QT interval prolongation
  7. QTc interval > 500 msec
  8. Current participation in any research study involving investigational drugs or device
  9. Inability or unwillingness to give informed consent
  10. Ongoing drug or alcohol abuse
  11. On any cannabinoid during the past month
  12. Women who are pregnant or breastfeeding
  13. Current diagnosis of cancer, with the exception of non-melanoma skin cancer
  14. Any factor, which would make it unlikely that the patient can comply with the study procedures
  15. Showing suicidal tendency as per the Columbia Suicide Severity Rating Scale (C-SSRS), administered at screening
  16. On digoxin and/or type 1 or 3 antiarrhythmics
  17. On immunosuppressive therapy with any of the following:

    1. Rilonacept
    2. Anakinra
    3. Canakinumab
    4. Methotrexate
    5. Azathioprine
    6. Cyclosporine
    7. Intravenous immune globulin (IVIG)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05494788

Layout table for location information
United States, Arizona
Pima Heart and Vascular Clinical Research
Tucson, Arizona, United States, 85719
United States, District of Columbia
MedStar Health Research Institute
Washington, District of Columbia, United States, 20010
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Minnesota
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States, 55407
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Vermont
University of Vermont Medical Center
Burlington, Vermont, United States, 05401
United States, Virginia
Virginia Commonwealth University Health
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Cardiol Therapeutics Inc.
Layout table for investigator information
Study Chair: Allen Klein, MD The Cleveland Clinic
Layout table for additonal information
Responsible Party: Cardiol Therapeutics Inc. Identifier: NCT05494788    
Other Study ID Numbers: Cardiol 100-004
First Posted: August 10, 2022    Key Record Dates
Last Update Posted: May 23, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease Attributes
Pathologic Processes
Heart Diseases
Cardiovascular Diseases